I believe there is a population of investors who have seen RXMD's amazing fundamentals ($18.3 million in revenues last year, on-track for $22 million this year, audited, profitable, etc.) but are understandably leery of diving into the pinks. There are others who don't even look at the pinks, and as such don't even know that RXMD exists.
Both groups will have a chance to look at RXMD when they move up to OTCQB, and the ones that jump in will do some very, very nice things for the share price.